Post-operative, Inpatient Rehabilitation After Lung Transplant Evaluation

Overview

This randomized, feasibility trial (n=40) will compare the effects of an intensive, twice daily inpatient physical rehabilitation program against standard care (once daily) following double lung transplantation.

Full Title of Study: “Post-operative, Inpatient Rehabilitation After Lung Transplant Evaluation: A Feasibility Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Care Provider, Outcomes Assessor)
  • Study Primary Completion Date: March 23, 2020

Detailed Description

This trial will involve the participation of patients post lung transplantation, in the initial post-operative period. Recruitment will take place as soon as the patient is medically safe and willing to commence physical rehabilitation within the intensive care unit. Current, standard care for inpatient physical rehabilitation post lung transplant involves a once daily session of physiotherapy for the duration of the patient's initial inpatient stay, and consists of early mobility, aerobic exercise, upper and lower limb strengthening and flexibility or core muscle re-training. This trial aims to assess the feasibility and safety of twice daily physical rehabilitation sessions during the post-operative period following lung transplantation. The content of the additional physical rehabilitation session will not differ from, but will complement current standard care, and will be delivered by a trained research assistant or physiotherapist. To the investigator's knowledge, there is no current evidence to support the dosage and intensity of inpatient physical rehabilitation following lung transplantation, and it is unsatisfactory to use evidence from other patient groups to guide practice in this area. To assess the feasibility of an intensive, inpatient physical rehabilitation program post lung transplantation, the investigators will collect the following data: Number of patients eligible for study inclusion; number of patients consented; number of additional, intensive physical rehabilitation sessions completed; reasons for non-completion of sessions; and attrition, or patient withdrawal rate. In order to assess the safety of the program, the investigators will also assess for evidence of early, acute rejection of the transplanted lungs based on the routine collection of tissue samples, and adverse events. Adverse events will be defined as any event likely caused by acute physical rehabilitation, including musculoskeletal injury, patient fall and surgical wound breakdown. These assessments will be complemented by a number of physical and psychological outcome measures and patient statistics, including tests of physical capacity, participation and strength, quality of life, requirements for additional physical rehabilitation and/or hospital readmissions within 10 weeks of study commencement, discharge destination and patient length of stay data. Assessments will be completed within 3 days of first time to mobilize, after three weeks and finally after 10 weeks post-transplant. The investigators hypothesise that an intensive, physical rehabilitation program will be safe and feasible to implement in the post-operative phase post lung transplantation, and that participants in the intensive rehabilitation group will be more active at 10 days, and at 10 weeks than those receiving standard, post lung transplant physical rehabilitation.

Interventions

  • Other: Physical rehabilitation.
    • Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.

Arms, Groups and Cohorts

  • Active Comparator: Control
    • Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
  • Experimental: Experimental
    • Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.

Clinical Trial Outcome Measures

Primary Measures

  • Ability to deliver intensive inpatient physical rehabilitation (feasibility).
    • Time Frame: Patient length of stay is typically two to three weeks following lung transplant surgery.
    • Quantified by number of patients eligible for inclusion; number of patients consented; number of additional, intensive physical rehabilitation sessions completed during the initial, inpatient stay post operatively; reasons for non-completion of sessions; and attrition. This will be aggregated into an overall percentage of successful delivery of intervention.
  • Incidence of treatment and non-treatment related adverse events (safety).
    • Time Frame: Patient length of stay is typically two to three weeks following lung transplant surgery.
    • Evidence of early, acute rejection on bronchoscopic biopsy and adverse events. Adverse events will be defined as any adverse outcome during the study period, including but not limited to events that could be related to acute physical rehabilitation such as musculoskeletal injury, patient fall and surgical wound dehiscence or breakdown.

Secondary Measures

  • Six-minute walk test.
    • Time Frame: Pre-transplant results if available. Repeated at 3 and 10 weeks.
    • Distance walked in six minutes.
  • Physical activity monitoring (Dynaport®).
    • Time Frame: 7 days (5 days of data) at post-operative day 10 and at 10 weeks.
    • Physical activity levels.
  • Pain visual analogue scale (VAS).
    • Time Frame: Once daily on physical activity monitoring days, from day 10 – 16 post-transplant, repeated for seven days at 10 weeks post-transplant.
    • 0-10 pain score.
  • EuroQol EQ-5D-5L.
    • Time Frame: Baseline (within 3 days from first time to mobilise), 3 weeks and 10 weeks post-transplant.
    • Health-related quality of life questionnaire.
  • Sit to stand test – 60 second.
    • Time Frame: Baseline (within 3 days from first time to mobilise), inpatient discharge (2-3 weeks), one month and three months.
    • Amount of sit-stands completed over 60 seconds.
  • Grip strength.
    • Time Frame: Baseline (within 3 days from first time to mobilise), 3 weeks and 10 weeks post-transplant.
    • Hand-held dynamometer.
  • Modified Iowa Level of Assistance Scale (MILOA).
    • Time Frame: Baseline (within 3 days from first time to mobilise), 3 weeks and 10 weeks post-transplant.
    • A valid, reliable and responsive scale of physical capacity in the post-operative patient.

Participating in This Clinical Trial

Inclusion Criteria

  • Medically stable and able to participate in physical rehabilitation as directed by the treating medical team and primary physiotherapist – All transplant indications will be included, including re-transplantation – Will include interstate patients (South Australia, Tasmania) as all patients routinely remain in Victoria attending post-transplant clinic and rehabilitation for three months post operatively Exclusion Criteria:

  • Medically unable to mobilise (e.g. cardiovascular instability) – Critically unwell (ECMO, CVVHDF etc.) – <18 years old (paediatric lung transplant) – Heart-lung transplant – Single lung transplant (SLTx) – Unable to provide written informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Alfred
  • Provider of Information About this Clinical Study
    • Principal Investigator: Benjamin Tarrant, Senior Clinician Physiotherapist – Lung Transplant – The Alfred
  • Overall Official(s)
    • Benjamin J Tarrant, B.Physio, Principal Investigator, The Alfred

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.